Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 1
1965 1
1968 1
1971 1
1973 2
1975 2
1977 2
1979 2
1980 2
1983 3
1985 3
1986 2
1987 2
1994 1
1996 2
1997 1
1998 2
1999 1
2000 3
2001 2
2002 2
2003 8
2004 1
2005 4
2006 6
2007 3
2008 7
2009 7
2010 2
2011 5
2012 6
2013 6
2014 6
2015 9
2016 2
2017 5
2018 1
2019 4
2020 2
2021 2
2022 2
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: hummel hd. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. Among authors: hummel hd. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Evolutionary trajectories of small cell lung cancer under therapy.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. George J, et al. Among authors: hummel hd. Nature. 2024 Mar;627(8005):880-889. doi: 10.1038/s41586-024-07177-7. Epub 2024 Mar 13. Nature. 2024. PMID: 38480884 Free PMC article.
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article. Clinical Trial.
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S; National Network Genomic Medicine Lung Cancer (nNGM). Janning M, et al. Among authors: hummel hd. Ann Oncol. 2022 Jun;33(6):602-615. doi: 10.1016/j.annonc.2022.02.225. Epub 2022 Mar 6. Ann Oncol. 2022. PMID: 35263633 Free article.
Protected Area management: Fusion and confusion with the ecosystem services approach.
Hummel C, Poursanidis D, Orenstein D, Elliott M, Adamescu MC, Cazacu C, Ziv G, Chrysoulakis N, van der Meer J, Hummel H. Hummel C, et al. Among authors: hummel h. Sci Total Environ. 2019 Feb 15;651(Pt 2):2432-2443. doi: 10.1016/j.scitotenv.2018.10.033. Epub 2018 Oct 6. Sci Total Environ. 2019. PMID: 30336433 Free article. Review.
Meta-analysis of multidecadal biodiversity trends in Europe.
Pilotto F, Kühn I, Adrian R, Alber R, Alignier A, Andrews C, Bäck J, Barbaro L, Beaumont D, Beenaerts N, Benham S, Boukal DS, Bretagnolle V, Camatti E, Canullo R, Cardoso PG, Ens BJ, Everaert G, Evtimova V, Feuchtmayr H, García-González R, Gómez García D, Grandin U, Gutowski JM, Hadar L, Halada L, Halassy M, Hummel H, Huttunen KL, Jaroszewicz B, Jensen TC, Kalivoda H, Schmidt IK, Kröncke I, Leinonen R, Martinho F, Meesenburg H, Meyer J, Minerbi S, Monteith D, Nikolov BP, Oro D, Ozoliņš D, Padedda BM, Pallett D, Pansera M, Pardal MÂ, Petriccione B, Pipan T, Pöyry J, Schäfer SM, Schaub M, Schneider SC, Skuja A, Soetaert K, Spriņģe G, Stanchev R, Stockan JA, Stoll S, Sundqvist L, Thimonier A, Van Hoey G, Van Ryckegem G, Visser ME, Vorhauser S, Haase P. Pilotto F, et al. Among authors: hummel h. Nat Commun. 2020 Jul 13;11(1):3486. doi: 10.1038/s41467-020-17171-y. Nat Commun. 2020. PMID: 32661354 Free PMC article.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, McComb M, Wittemer-Rump S, Koca G, Stienen S, Bargou RC, Hummel HD, Loidl W, Grüllich C, Eggert T, Tran B, Mytych DT. Penny HL, et al. Among authors: hummel hd. Front Immunol. 2023 Oct 23;14:1261070. doi: 10.3389/fimmu.2023.1261070. eCollection 2023. Front Immunol. 2023. PMID: 37942314 Free PMC article.
Therapy of highly active pediatric multiple sclerosis.
Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, Brück W, Gärtner J. Huppke P, et al. Among authors: hummel h. Mult Scler. 2019 Jan;25(1):72-80. doi: 10.1177/1352458517732843. Epub 2017 Sep 21. Mult Scler. 2019. PMID: 28933245
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.
Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Valdagni R, et al. Among authors: hummel h. Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43. doi: 10.1016/j.critrevonc.2015.05.014. Epub 2015 Jun 5. Crit Rev Oncol Hematol. 2015. PMID: 26092320 Review.
122 results